Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wendy Leng

Urogynecology and Reconstructive Pelvic Surgery Fort Worth, TX Medical Doctor

NPI 1891769022 CMS profile 445859

6801 Oakmont Blvd Ste 102, Ste 102, Fort Worth, TX 76132

Open in the dashboard

General payments

$9,736

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wendy Leng of Fort Worth, TX is reported in the CMS Open Payments database as having received $9,736 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,236 74
2024 General $1,666 57
2023 General $893 39
2022 General $767 31
2021 General $836 39
2020 General $897 39
2019 General $2,441 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Leng
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Wendy Leng were reported at $2,236. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Wendy Leng Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $2,441 $799 $319–$2,013 $163
2020 $897 $384 $158–$1,360 $114
2021 $836 $641 $247–$2,515 $132
2022 $767 $843 $347–$2,794 $149
2023 $893 $819 $308–$2,302 $160
2024 $1,666 $882 $306–$2,459 $164
2025 $2,236 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,727 75 payments
  2. Medtronic USA, Inc. $1,674 24 payments
  3. Caldera Medical, Inc $923 11 payments
  4. Astellas Pharma US Inc $749 43 payments
  5. Sumitomo Pharma America, Inc. $559 54 payments
  6. Boston Scientific Corporation $462 14 payments
  7. AbbVie, Inc. $455 17 payments
  8. Axonics Modulation Technologies, Inc. $450 20 payments
  9. Janssen Biotech, Inc. $257 5 payments
  10. Valencia Technologies Corporation $178 4 payments
  11. Other $1,302 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,161 293 payments
  2. Consulting Fee $1,340 2 payments
  3. Travel and Lodging $944 9 payments
  4. Grant $114 1 payment
  5. Education $99 2 payments
  6. Gift $79 3 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $1,587 58 payments
  2. INTERSTIM Sacral Nerve Stimulation $1,034 23 payments
  3. Desara $923 11 payments
  4. Vertessa $700 1 payment
  5. MYRBETRIQ $616 40 payments
  6. GEMTESA $552 54 payments
  7. ERLEADA $233 4 payments
  8. BOTOX $191 8 payments
  9. eCoin Device Kit $178 4 payments
  10. iTIND System $178 7 payments
  11. Other $2,473 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

970

Median for Urology: 1,053

Drug cost

$166,963

Median for Urology: $101,464

Branded share of claims

33.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 108 $88,441
Myrbetriq Mirabegron Brand 67 $41,973
Methenamine Hippurate Generic 350 $24,953
Estradiol Generic 95 $5,924
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 71 $2,254
Oxybutynin Chloride Er Oxybutynin Chloride Brand 66 $1,571
Solifenacin Succinate Generic 20 $803
Tamsulosin Hcl Generic 39 $543
Tramadol Hcl Generic 89 $245
Cephalexin Generic 52 $182

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$374,353

Of which drugs: $19,353

Medicare patients

807

Average age 75

Services billed

10,615

644 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 34%
Diabetes 28%
Chronic kidney disease 28%
Ischemic heart disease 27%
Osteoporosis 24%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 26 3,900 $19,349

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $131
$131 108 —
BOTOX
  • AbbVie, Inc. $99
$99 — 3,900
ERLEADA
  • Janssen Biotech, Inc. $58
$58 — —
AKEEGA
  • Janssen Biotech, Inc. $58
$58 — —
AVYCAZ
  • AbbVie, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record